Danaher Co. (NYSE:DHR) Stock Position Increased by Rosenberg Matthew Hamilton

Rosenberg Matthew Hamilton grew its position in Danaher Co. (NYSE:DHR) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 969 shares of the conglomerate’s stock after purchasing an additional 54 shares during the period. Rosenberg Matthew Hamilton’s holdings in Danaher were worth $222,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in DHR. Benjamin Edwards Inc. increased its position in Danaher by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares during the period. Wedge Capital Management L L P NC increased its holdings in shares of Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Certified Advisory Corp raised its stake in shares of Danaher by 4.5% during the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 40 shares in the last quarter. Meridian Financial Partners LLC lifted its holdings in Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares during the period. Finally, Kovack Advisors Inc. increased its stake in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after buying an additional 41 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $239.83 on Tuesday. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $173.22 billion, a price-to-earnings ratio of 45.77, a P/E/G ratio of 4.32 and a beta of 0.83. The business’s 50-day moving average is $235.52 and its 200-day moving average is $253.65.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities research analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DHR. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Citigroup cut their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Stifel Nicolaus raised their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Guggenheim initiated coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target on the stock. Finally, KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.